Daxor Co. (NASDAQ:DXR) Sees Large Growth in Short Interest

Daxor Co. (NASDAQ:DXR) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 15th total of 8,400 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 16,800 shares, the days-to-cover ratio is currently 0.5 days.

Daxor Stock Performance

Shares of Daxor stock traded up $0.41 on Friday, hitting $8.50. 1,102 shares of the company traded hands, compared to its average volume of 5,653. Daxor has a 12-month low of $7.19 and a 12-month high of $10.02. The firm’s 50-day simple moving average is $8.56 and its 200 day simple moving average is $8.80.

Institutional Investors Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC lifted its holdings in shares of Daxor Co. (NASDAQ:DXR) by 34.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned about 0.30% of Daxor worth $126,000 as of its most recent filing with the SEC. 1.34% of the stock is owned by hedge funds and other institutional investors.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.